- Home
- CELZ vs GNPX Comparison
CELZ vs GNPX Comparison
Compare CELZ & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELZ
- GNPX
- Stock Information
- Founded
- CELZ 1998
- GNPX 2009
- Country
- CELZ United States
- GNPX United States
- Employees
- CELZ N/A
- GNPX N/A
- Industry
- CELZ Biotechnology: Pharmaceutical Preparations
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- CELZ Health Care
- GNPX Health Care
- Exchange
- CELZ Nasdaq
- GNPX Nasdaq
- Market Cap
- CELZ 5.5M
- GNPX 7.0M
- IPO Year
- CELZ N/A
- GNPX 2018
- Fundamental
- Price
- CELZ $2.14
- GNPX $0.29
- Analyst Decision
- CELZ
- GNPX Strong Buy
- Analyst Count
- CELZ 0
- GNPX 1
- Target Price
- CELZ N/A
- GNPX $10.00
- AVG Volume (30 Days)
- CELZ 63.2K
- GNPX 2.6M
- Earning Date
- CELZ 05-20-2025
- GNPX 05-16-2025
- Dividend Yield
- CELZ N/A
- GNPX N/A
- EPS Growth
- CELZ N/A
- GNPX N/A
- EPS
- CELZ N/A
- GNPX N/A
- Revenue
- CELZ $11,000.00
- GNPX N/A
- Revenue This Year
- CELZ N/A
- GNPX N/A
- Revenue Next Year
- CELZ N/A
- GNPX N/A
- P/E Ratio
- CELZ N/A
- GNPX N/A
- Revenue Growth
- CELZ 22.22
- GNPX N/A
- 52 Week Low
- CELZ $1.69
- GNPX $0.22
- 52 Week High
- CELZ $6.90
- GNPX $4.09
- Technical
- Relative Strength Index (RSI)
- CELZ 48.39
- GNPX 48.62
- Support Level
- CELZ $1.92
- GNPX $0.27
- Resistance Level
- CELZ $2.12
- GNPX $0.36
- Average True Range (ATR)
- CELZ 0.15
- GNPX 0.03
- MACD
- CELZ 0.06
- GNPX 0.01
- Stochastic Oscillator
- CELZ 85.29
- GNPX 46.31
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.